Top Markets
Coin of the day
Medivir AB (publ) Medivir AB (publ)

Medivir AB (publ)

MVIR-B
Rank in Stocks #29652
Medivir AB (publ) is a pharmaceutical company established in 1987 and... Medivir AB (publ) is a pharmaceutical company established in 1987 and headquartered in Huddinge, Sweden. It is dedicated to the research, development, and global commercialization of medicines, with a primary focus on oncology. The company currently markets Zoviduo (formerly Xerclear) for the treatment of labial herpes. Its robust development pipeline includes Remetinostat, targeting MF cutaneous T-cell lymphoma and basal cell carcinoma; MIV-818, aimed at liver cancer; and MIV-711, being advanced for osteoarthritis. Additionally, Medivir is progressing Birinapant and IGM-8444 for various solid tumor indications. Collaborative efforts are also key to its strategy, including a research partnership with SciLifeLab's Drug Discovery and Development Platform to discover antivirals for SARS CoV-2, alongside licensing agreements with Tango Therapeutics for a preclinical research program and with Ubiquigent Limited for the USP7 preclinical research program.
Share Price
$0.68377137
Last synced: 2023-05-23
Market Cap
$20.23M
Change (1 day)
-0.60%
Change (1 year)
0.00%
Country
SE
Trade Medivir AB (publ) (MVIR-B)

Category

P/B ratio for Medivir AB (publ) (MVIR-B)
P/B ratio as of 2026 TTM: 0
According to Medivir AB (publ) latest financial reports and stock price the company's current price-to-book ratio (TTM) is 0. At the end of 2026 the company had a P/B ratio of 0.
P/B ratio history for Medivir AB (publ) from 2026 to 2026
P/B ratio at the end of each year
Year P/B Ratio Change
Not enough data for the provided dates.
P/B ratio for similar companies or competitors
Company P/B Ratio P/B Ratio Difference Country
6.3419 -
US
6.2413 -
NL
3.7087 -
US
2.5054 -
AU
- -
CH